- Home
- SAIH vs SNTI Comparison
SAIH vs SNTI Comparison
Compare SAIH & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- SNTI
- Stock Information
- Founded
- SAIH 2019
- SNTI 2016
- Country
- SAIH Singapore
- SNTI United States
- Employees
- SAIH N/A
- SNTI N/A
- Industry
- SAIH
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- SAIH
- SNTI Health Care
- Exchange
- SAIH NYSE
- SNTI Nasdaq
- Market Cap
- SAIH 17.1M
- SNTI 19.1M
- IPO Year
- SAIH N/A
- SNTI N/A
- Fundamental
- Price
- SAIH $0.70
- SNTI $4.67
- Analyst Decision
- SAIH
- SNTI Strong Buy
- Analyst Count
- SAIH 0
- SNTI 1
- Target Price
- SAIH N/A
- SNTI $12.00
- AVG Volume (30 Days)
- SAIH 89.5K
- SNTI 115.8K
- Earning Date
- SAIH 11-13-2024
- SNTI 11-14-2024
- Dividend Yield
- SAIH N/A
- SNTI N/A
- EPS Growth
- SAIH N/A
- SNTI N/A
- EPS
- SAIH N/A
- SNTI N/A
- Revenue
- SAIH $6,954,000.00
- SNTI N/A
- Revenue This Year
- SAIH N/A
- SNTI $11.52
- Revenue Next Year
- SAIH N/A
- SNTI $78.57
- P/E Ratio
- SAIH N/A
- SNTI N/A
- Revenue Growth
- SAIH N/A
- SNTI N/A
- 52 Week Low
- SAIH $0.54
- SNTI $1.52
- 52 Week High
- SAIH $1.80
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- SNTI 56.65
- Support Level
- SAIH N/A
- SNTI $3.72
- Resistance Level
- SAIH N/A
- SNTI $4.93
- Average True Range (ATR)
- SAIH 0.00
- SNTI 0.46
- MACD
- SAIH 0.00
- SNTI 0.01
- Stochastic Oscillator
- SAIH 0.00
- SNTI 81.82
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the advanced Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, advanced liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.